• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Survival increased in chronic lymphocytic leukemia patients treated with ibrutinib and rituximab

byDayton McMillan
August 3, 2019
in Chronic Disease, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Previously untreated chronic lymphocytic leukemia (CLL) patients experienced increased progression-free and overall survival when treated with ibrutinib-rituximab compared to current standard chemoimmunotherapy.

2. Rates of high grade adverse events were similar between treatment groups.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: CLL is a common hematologic malignancy often treated with a combination of fludarabine, cyclophosphamide, and rituximab. While efficacious, there are notable side effects to the chemoimmunotherapy regimen. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has shown efficacy in patients with relapsed or refractory CLL, though how it performs as a first line treatment is not yet determined. This phase 3 trial evaluated ibrutinib-rituximab in comparison to standard chemoimmunotherapy in untreated CLL patients and found both progression-free and overall survival to be improved relative to standard therapy at almost 3 years after treatment initiation. The incidence of grade 3 or 4 adverse events was similar in the treatment groups, though infections were more common in the ibrutinib-rituximab group.

This randomized trial provides support for use of a new regimen as a first line treatment in CLL patients. Strengths of the study include its randomized design, mutational analysis of immunoglobulin heavy-chain variable region (IGHV) patients, and extensive subgroup analysis. The utility of this study is limited by its discordance with other trials evaluating ibrutinib in CLL.

Click to read the study in NEJM

Relevant Reading: Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

RELATED REPORTS

United States-based chemotherapy regimen for Ewing sarcoma is more effective and safer than the standard European regimen

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer

In-Depth [randomized controlled trial]: This phase 3, multicenter, randomized controlled trial enrolled patients between 2014 and 2016. Eligible patients were under 70 years of age and had previously untreated CLL or the small lymphocytic lymphoma (SLL) subtype of CLL. Patients with a 17p13 mutation were excluded because of known poor response to chemoimmunotherapy treatment. Patients were stratified and randomized to an ibrutinib-rituximab (n=354) or chemoimmunotherapy group receiving fludarabine, cyclophosphamide, and rituximab (n=175). At a 3 year timepoint, the primary endpoint of progression-free survival was 89.4% (95% confidence interval [CI], 86.0 to 93.0) in the ibrutinib-rituximab and 72.9% (95% CI, 65.3 to 81.3) in the chemoimmunotherapy group (hazard ratio for progression or death, 0.35; 95% CI, 0.22 to 0.56; P<0.001). Overall survival in the ibrutinib-rituximab group was 98.8% (95% CI, 97.6 to 100) compared to 91.5% (95% CI, 86.2 to 97.0) in the chemoimmunotherapy group (hazard ratio for death, 0.17; 95% CI, 0.05 to 0.54; P<0.001). In prespecified subgroup analysis ibrutinib-rituximab treatment was superior for patients regardless of age, sex, or Rai stage. An overall response occurred more in the ibrutinib-rituximab patients. Grade 3 or 4 adverse events occurred in approx. 80% of patients in both treatment groups.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic lymphocytic leukemia (CLL)cyclophosphamidefludarabineIbrutinibrituximabsmall lymphocytic lymphoma
Previous Post

#VisualAbstract: Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease

Next Post

Intensive blood pressure management reduces risk of recurrent stroke

RelatedReports

Increased frailty associated with childhood cancer survivorship
Chronic Disease

United States-based chemotherapy regimen for Ewing sarcoma is more effective and safer than the standard European regimen

November 9, 2022
#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma
StudyGraphics

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

October 19, 2022
#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer
StudyGraphics

#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer

October 11, 2022
Autologous hematopoietic stem cell transplantation associated with long-term remission in myasthenia gravis
Chronic Disease

Single dose of rituximab for new-onset myasthenia gravis associated with reduced risk of disease manifestations – The RINOMAX Randomized Clinical Trial

September 28, 2022
Next Post
UTI associated with increased risk of preeclampsia

Intensive blood pressure management reduces risk of recurrent stroke

Cerebral protection device effective in patients undergoing transcatheter aortic valve implantation

Renin-angiotensin system inhibition following transcatheter aortic valve replacement linked with lower cardiac mortality

Quick Take: Prevalence and Treatment of Depression, Anxiety, and Conduct Problems in US Children

Adults with cerebral palsy at increased risk for mental health disorders

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options